Bicyclic heterocycles as FGFR inhibitors
US-9533984-B2 · Jan 3, 2017 · US
Substituted tricyclic compounds as FGFR inhibitors
US11053246B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11053246-B2 |
| Application number | US-202016842558-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 7, 2020 |
| Priority date | Jun 13, 2012 |
| Publication date | Jul 6, 2021 |
| Grant date | Jul 6, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating cancer in a patient comprising administering to said patient a therapeutically effective amount of 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, or a pharmaceutically acceptable salt thereof, wherein said cancer is selected from colorectal cancer, kidney cancer, prostate cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer, melanoma, and rhabdosarcoma. 2. The method of claim 1 , wherein said cancer is colorectal cancer. 3. The method of claim 1 , wherein said cancer is kidney cancer. 4. The method of claim 1 , wherein said cancer is prostate cancer. 5. The method of claim 1 , wherein said cancer is gall bladder cancer. 6. The method of claim 1 , wherein said cancer is pancreatic cancer. 7. The method of claim 1 , wherein said cancer is thyroid cancer. 8. The method of claim 1 , wherein said cancer is skin cancer. 9. The method of claim 1 , wherein said cancer is melanoma. 10. The method of claim 1 , wherein said cancer is rhabdosarcoma.
Assignees
Inventors
Classifications
- C07D471/14Primary
Ortho-condensed systems · CPC title
Antineoplastic agents · CPC title
for joint disorders, e.g. arthritis, arthrosis · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11053246B2 cover?
- The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
- Who is the assignee on this patent?
- Incyte Corp, Incyte Holdings Corp
- What technology area does this patent fall under?
- Primary CPC classification C07D471/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).